{"id":1952,"date":"2026-07-16T19:06:07","date_gmt":"2026-07-16T18:06:07","guid":{"rendered":"https:\/\/hematologuetanger.com\/?p=1952"},"modified":"2026-07-23T09:33:22","modified_gmt":"2026-07-23T08:33:22","slug":"management-of-immunosuppression-in-post-transplant-lymphoproliferative-disorders-treated-with-car-t-cells","status":"publish","type":"post","link":"https:\/\/hematologuetanger.com\/ar\/management-of-immunosuppression-in-post-transplant-lymphoproliferative-disorders-treated-with-car-t-cells\/","title":{"rendered":"Management of immunosuppression in post-\u00ad transplant lymphoproliferative disorders treated with CAR T cells"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The use of chimeric antigen receptor (CAR) T-cell therapy for post-transplant lymphoproliferative disorders (PTLD) is limited. Here, we report the successful management of a 24 years old patient with refractory EBV-positive PTLD treated with axicabtagene ciloleucel. We also review the literature to further delineate the role of CAR T-cells in this population and refine the management of immunosuppressive treatments during the procedure.<\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/hematologuetanger.com\/wp-content\/uploads\/2026\/07\/17926400.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 17926400.\"><\/object><a id=\"wp-block-file--media-02d99da8-22c4-4566-815a-488a4130d177\" href=\"https:\/\/hematologuetanger.com\/wp-content\/uploads\/2026\/07\/17926400.pdf\">17926400<\/a><a href=\"https:\/\/hematologuetanger.com\/wp-content\/uploads\/2026\/07\/17926400.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-02d99da8-22c4-4566-815a-488a4130d177\">T\u00e9l\u00e9charger<\/a><\/div>","protected":false},"excerpt":{"rendered":"<p>The use of chimeric antigen receptor (CAR) T-cell therapy for post-transplant lymphoproliferative disorders (PTLD) is limited. Here, we report the successful management of a 24 years old patient with refractory EBV-positive PTLD treated with axicabtagene ciloleucel. We also review the literature to further delineate the role of CAR T-cells in this population and refine the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1952","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/posts\/1952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/comments?post=1952"}],"version-history":[{"count":3,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/posts\/1952\/revisions"}],"predecessor-version":[{"id":2056,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/posts\/1952\/revisions\/2056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/media\/2057"}],"wp:attachment":[{"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/media?parent=1952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/categories?post=1952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hematologuetanger.com\/ar\/wp-json\/wp\/v2\/tags?post=1952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}